HIKMA, A CONVINCINGLY DIFFERENT PHARMA (ADD; 12% UPSIDE)
23/12/20 -"Since our last endorsement in April 2020, it has been a seesaw ride for the generic drugs manufacturer, Hikma (Add, UK). While the reiteration of its FY20 targets (in May), at a time when peers were ..."
Pages
53
Language
English
Published on
23/12/20
You may also be interested by these reports :
14/11/25
The Q3 results surpassed expectations, driven by strong demand for depression and migraine medicines. Consequently, the management upgraded its ...
13/11/25
The Q3 results exceeded the street’s expectations, driven by healthy top-line growth across all segments and a profitability beat (also aided by a ...
12/11/25
The Q3 profitability beat was driven by Crop Science, though Pharmaceuticals witnessed lower operating profits. Also, the management maintained its ...
10/11/25
The US government has agreed with Novo and Lilly to lower their weight-loss drugs’ prices, mainly in return for a three-year tariff exemption and ...